Sudden onset vision loss: an atypical presentation of giant cell arteritis and myeloproliferative neoplasm

• 1 Royal Adelaide Hospital, Adelaide, SA
• 2 South Australian Institute of Ophthalmology, Adelaide, SA
• 3 University of Adelaide, Adelaide, SA

---

• 1. Varma DD, Cugati S, Lee AW, Chen CS. A review of central retinal artery occlusion: clinical presentation and management. Eye (Lond) 2013; 27: 688–697.
• 2. Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol 2005; 140: 376–391.
• 3. Langabeer SE. The JAK2 V617F mutation in retinal vein or artery occlusion. EXCLI J 2019; 18: 127–128.
• 4. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017; 129: 680–692.
• 5. Forsyth C, Melville K, Tiley C. The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications. Pathology 2018; 50: 775–776.
• 6. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115: 778–782.
• 7. Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C‐reactive protein with an elevated erythrocyte sedimentation rate in biopsy‐proven giant cell arteritis. Ophthalmology 2006; 113: 1842–1845.
• 8. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285–296.